Therapeutic vaccination to treat chronic infectious diseases: Current clinical developments using MVA-based vaccines

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 12, 2012, Pages 1746-1757

  Boukhebza, Houda ^a   Bellon, Nadine ^a   Limacher, Jean Marc ^a   Inchauspé, Geneviève ^a  

^a TRANSGENE S A   (France)

Author keywords

Clinical trials; Infectious diseases; Modified virus ankara; Poxvirus; Therapeutic vaccines

Indexed keywords

ANTIRETROVIRUS AGENT; BCG VACCINE; DNA VACCINE; HEPATITIS C VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MODIFIED VIRUS ANKARA VACCINE; PEGINTERFERON; PLACEBO; PLASMID DNA; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; APLASTIC ANEMIA; CANCER REGRESSION; CHRONIC DISEASE; CLINICAL STUDY; CYTOKINE PRODUCTION; DRUG DESIGN; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FLU LIKE SYNDROME; GENOME ANALYSIS; HEPATITIS C; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INJECTION SITE REACTION; INNATE IMMUNITY; MODIFIED VIRUS ANKARA POXVIRUS; NONHUMAN; PAPILLOMAVIRUS INFECTION; POXVIRUS; REVIEW; THROMBOCYTOPENIA; TUBERCULOSIS; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRUS ATTENUATION; VIRUS REPLICATION; VIRUS STRAIN;

CLINICAL TRIALS; INFECTIOUS DISEASES; MODIFIED VIRUS ANKARA; POXVIRUS; THERAPEUTIC VACCINES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CHRONIC DISEASE; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG CARRIERS; GENETIC VECTORS; HEPATITIS, VIRAL, HUMAN; HUMANS; IMMUNOTHERAPY; PAPILLOMAVIRUS INFECTIONS; TUBERCULOSIS; UNITED STATES; VACCINES; VACCINIA VIRUS;

EID: 84872250960     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.21689     Document Type: Review

References (77)

1. Abès R, Gélizé E, Fridman WH, Teillaud JL. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 2010; 116:926-34; PMID:20439625; http://dx.doi.org/10.1182/ blood-2009-10-248609.
2. Taylor C, Hershman D, Shah N, Suciu-Foca N, Petrylak DP, Taub R, et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 2007; 13:5133-43; PMID:17785568; http://dx.doi.org/10.1158/1078-0432.CCR-07-0507.
3. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al.; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294.
4. Acres B, Bonnefoy JY. Clinical development of MVA-based therapeutic cancer vaccines. Expert Rev Vaccines 2008; 7:889-93; PMID:18767940; http://dx.doi.org/10.1586/14760584.7.7.889.
5. Michel ML, Deng Q, Mancini-Bourgine M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol 2011; 54:1286-96; PMID:21238516; http://dx.doi.org/10. 1016/j.jhep.2010.12.031.
6. Inchauspe G, Bach G, Martin P, Bonnefoy JY. Vaccination against hepatitis B and C: towards therapeutic application. Int Rev Immunol 2009; 28:7-19; PMID:19241251; http://dx.doi.org/10.1080/08830180802488436.
7. Cid-Arregui A. Therapeutic vaccines against human papillomavirus and cervical cancer. Open Virol J 2009; 3:67-83; PMID:19915722; http://dx.doi.org/ 10.2174/1874357900903010067.
8. Mayr A, Stickl H, Müller HK, Danner K, Singer H. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl Bakteriol B 1978; 167:375-90; PMID:219640.
9. Sutter G, Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 2003; 3:263-71; PMID:14529359; http://dx.doi.org/10.2174/ 1568005033481123.
10. Antoine G, Scheiflinger F, Dorner F, Falkner FG. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 1998; 244:365-96; PMID:9601507; http://dx.doi.org/10. 1006/viro.1998.9123.
11. Tolonen N, Doglio L, Schleich S, Krijnse Locker J. Vaccinia virus DNA replication occurs in endoplasmic reticulum-enclosed cytoplasmic mini-nuclei. Mol Biol Cell 2001; 12:2031-46; PMID:11452001.
12. Moss B. Poxvirus entry and membrane fusion. Virology 2006; 344:48-54; PMID:16364735; http://dx.doi.org/10.1016/j.virol.2005.09.037.
13. Gallego-Gómez JC, Risco C, Rodríguez D, Cabezas P, Guerra S, Carrascosa JL, et al. Differences in virus-induced cell morphology and in virus maturation between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia virus in infected human cells. J Virol 2003; 77:10606-22; PMID:12970445; http://dx.doi.org/10.1128/JVI.77.19.10606-10622.2003.
14. Sancho MC, Schleich S, Griffiths G, Krijnse-Locker J. The block in assembly of modified vaccinia virus Ankara in HeLa cells reveals new insights into vaccinia virus morphogenesis. J Virol 2002; 76:8318-34; PMID:12134037; http://dx.doi.org/10.1128/JVI.76.16.8318-8334.2002.
15. Drexler I, Heller K, Wahren B, Erfle V, Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 1998; 79:347-52; PMID:9472619.
16. Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A 1992; 89:10847-51; PMID:1438287; http://dx.doi.org/10.1073/pnas.89.22.10847.
17. Pastoret PP, Vanderplasschen A. Poxviruses as vaccine vectors. Comp Immunol Microbiol Infect Dis 2003; 26:343-55; PMID:12818621; http://dx.doi.org/10.1016/S0147-9571(03)00019-5.
18. Staib C, Drexler I, Sutter G. Construction and isolation of recombinant MVA. Methods Mol Biol 2004; 269:77-100; PMID:15114009.
19. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392:86-9; PMID:9510252; http://dx.doi.org/10.1038/32183.
20. Kastenmuller W, Drexler I, Ludwig H, Erfle V, Peschel C, Bernhard H, et al. Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity. Virology 2006; 350:276-88; PMID:16595141; http://dx.doi.org/10.1016/j.virol.2006.02.039.
21. Sánchez-Puig JM, Sánchez L, Roy G, Blasco R. Susceptibility of different leukocyte cell types to Vaccinia virus infection. Virol J 2004; 1:10; PMID:15555076; http://dx.doi.org/10.1186/1743-422X-1-10.
22. Liu L, Chavan R, Feinberg MB. Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo. BMC Immunol 2008; 9:15; PMID:18412969; http://dx.doi.org/10.1186/1471-2172-9-15.
23. Brandler S, Lepelley A, Desdouits M, Guivel-Benhassine F, Ceccaldi PE, Lévy Y, et al. Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect. J Virol 2010; 84:5314-28; PMID:20219934; http://dx.doi.org/10.1128/JVI.02329-09.
24. Guerra S, Nájera JL, González JM, López- Fernández LA, Climent N, Gatell JM, et al. Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J Virol 2007; 81:8707-21; PMID:17537851; http://dx.doi.org/10.1128/JVI.00444-07.
25. Gasteiger G, Kastenmuller W, Ljapoci R, Sutter G, Drexler I. Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. J Virol 2007; 81:11925-36; PMID:17699574; http://dx.doi.org/10.1128/JVI.00903-07.
26. Climent N, Guerra S, García F, Rovira C, Miralles L, Gómez CE, et al. Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals. PLoS One 2011; 6:e19644; PMID:21625608; http://dx.doi.org/10.1371/journal.pone. 0019644.
27. Flechsig C, Suezer Y, Kapp M, Tan SM, Löffler J, Sutter G, et al. Uptake of antigens from modified vaccinia Ankara virus-infected leukocytes enhances the immunostimulatory capacity of dendritic cells. Cytotherapy 2011; 13:739-52; PMID:21250864; http://dx.doi.org/10.3109/14653249.2010.549123.
28. Lehmann MH, Kastenmuller W, Kandemir JD, Brandt F, Suezer Y, Sutter G. Modified vaccinia virus ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression. J Virol 2009; 83:2540-52; PMID:19129447; http://dx.doi.org/10.1128/JVI.01884-08.
29. Greiner S, Humrich JY, Thuman P, Sauter B, Schuler G, Jenne L. The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity. Clin Exp Immunol 2006; 146:344-53; PMID:17034588; http://dx.doi.org/10.1111/j.1365-2249.2006.03177.x.
30. Pascutti MF, Rodríguez AM, Falivene J, Giavedoni L, Drexler I, Gherardi MM. Interplay between modified vaccinia virus Ankara and dendritic cells: phenotypic and functional maturation of bystander dendritic cells. J Virol 2011; 85:5532-45; PMID:21411535; http://dx.doi.org/10.1128/JVI.02267-10.
31. Barbalat R, Lau L, Locksley RM, Barton GM. Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands. Nat Immunol 2009; 10:1200-7; PMID:19801985; http://dx.doi.org/10.1038/ni.1792.
32. Zhu J, Martinez J, Huang X, Yang Y. Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta. Blood 2007; 109:619-25; PMID:16973959; http://dx.doi.org/10.1182/blood-2006-06- 027136.
33. Delaloye J, Roger T, Steiner-Tardivel QG, Le Roy D, Knaup Reymond M, Akira S, et al. Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog 2009; 5:e1000480; PMID:19543380; http://dx.doi.org/10.1371/journal.ppat.1000480.
34. Waibler Z, Anzaghe M, Ludwig H, Akira S, Weiss S, Sutter G, et al. Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses. J Virol 2007; 81:12102-10; PMID:17855554; http://dx.doi.org/10.1128/JVI.01190-07.
35. Samuelsson C, Hausmann J, Lauterbach H, Schmidt M, Akira S, Wagner H, et al. Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J Clin Invest 2008; 118:1776-84; PMID:18398511; http://dx.doi.org/10.1172/JCI33940.
36. Myskiw C, Arsenio J, Booy EP, Hammett C, Deschambault Y, Gibson SB, et al. RNA species generated in vaccinia virus infected cells activate cell type-specific MDA5 or RIG-I dependent interferon gene transcription and PKR dependent apoptosis. Virology 2011; 413:183-93; PMID:21354589; http://dx.doi.org/10.1016/j.virol.2011.01.034.
37. Blanchard TJ, Alcami A, Andrea P, Smith GL. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 1998; 79:1159-67; PMID:9603331.
38. Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR, et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009; 458:514-8; PMID:19158675; http://dx.doi.org/10.1038/nature07725.
39. Wenzel M, Wunderlich M, Besch R, Poeck H, Willms S, Schwantes A, et al. Cytosolic DNA triggers mitochondrial apoptosis via DNA damage signaling proteins independently of AIM2 and RNA polymerase III. J Immunol 2012; 188:394-403; PMID:22140256; http://dx.doi.org/10.4049/jimmunol.1100523.
40. Verheust C, Goossens M, Pauwels K, Breyer D. Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination. Vaccine 2012; 30:2623-32; PMID:22342706; http://dx.doi.org/10.1016/ j.vaccine.2012.02.016.
41. Esteban M. Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS. 2009; 5:867-71.
42. Cosma A, Nagaraj R, Bühler S, Hinkula J, Busch DH, Sutter G, et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 2003; 22:21-9; PMID:14604567; http://dx.doi.org/10.1016/S0264-410X(03)00538-3.
43. Harrer E, Bäuerle M, Ferstl B, Chaplin P, Petzold B, Mateo L, et al. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antivir Ther 2005; 10:285-300; PMID:15865223.
44. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121:621-32; PMID:17405118; http://dx.doi.org/10.1002/ijc.22527.
45. http://globocan.iarc.fr/.
46. Cid-Arregui A. Prophylactic HPV vaccines. Open Vaccine J 2012; In press.
47. Dowhanick JJ, McBride AA, Howley PM. Suppression of cellular proliferation by the papillomavirus E2 protein. J Virol 1995; 69:7791-9; PMID:7494290.
48. Corona Gutierrez CM, Tinoco A, Navarro T, Contreras ML, Cortes RR, Calzado P, et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther 2004; 15:421-31; PMID:15144573; http://dx.doi.org/10.1089/10430340460745757.
49. García-Hernández E, González-Sánchez JL, Andrade-Manzano A, Contreras ML, Padilla S, Guzmán CC, et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 2006; 13:592-7; PMID:16456551; http://dx.doi.org/10.1038/sj.cgt.7700937.
50. Albarran Y, Carvajal A, de la Garza A, Cruz Quiroz BJ, Vazquez Zea E, Díaz Estrada I, Mendez Fuentez E, et al. MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study. BioDrugs 2007; 21:47-59; PMID:17263589; http://dx.doi.org/10.2165/00063030-200721010-00006.
51. Brun JL, Dalstein V, Leveque J, Mathevet P, Raulic P, Baldauf JJ, et al. Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am J Obstet Gynecol 2011; 204:169, e1-8; PMID:21284968; http://dx.doi.org/10.1016/j.ajog.2010.09.020.
52. Psyrri A, Boutati E, Karageorgopoulou S. Human papillomavirus in head and neck cancers: biology, prognosis, hope of treatment, and vaccines. Anticancer Drugs 2011; 22:586-90; PMID:21403517; http://dx.doi.org/10.1097/CAD. 0b013e328344ec44.
53. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-67; PMID:16122679; http://dx.doi.org/10.1016/S1473-3099(05)70216-4.
54. Poordad F, McCone J Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al.; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-206; PMID:21449783; http://dx.doi.org/10. 1056/NEJMoa1010494.
55. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al.; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-16; PMID:21696307; http://dx.doi.org/10.1056/NEJMoa1012912.
56. Welsch C, Jesudian A, Zeuzem S, Jacobson I. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 2012; 61(Suppl 1):i36-46; PMID:22504918; http://dx.doi.org/10.1136/gutjnl-2012- 302144.
57. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194:1395-406; PMID:11714747; http://dx.doi.org/10.1084/jem.194.10. 1395.
58. Wertheimer AM, Miner C, Lewinsohn DM, Sasaki AW, Kaufman E, Rosen HR. Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology 2003; 37:577-89; PMID:12601356; http://dx.doi.org/10.1053/jhep.2003.50115.
59. Fournillier A, Gerossier E, Evlashev A, Schmitt D, Simon B, Chatel L, et al. An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses. Vaccine 2007; 25:7339-53; PMID:17875349; http://dx.doi.org/10.1016/j.vaccine.2007.08.020.
60. Habersetzer F, Honnet G, Bain C, Maynard-Muet M, Leroy V, Zarski JP, et al. A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology 2011; 141:890-9 e1-4.
61. Wedemeyer H, Janczewska KE, Mazur W, Stanciu C, Habersetzer F, Carreno V. HCVac study: antiviral activity of TG4040 therapeutic vaccination in genotype- 1 chronic HCV patients. 62nd Ann Meeting Am Ass Study Liver Dis (AASLD) 2011; poster 1336.
62. Cavenaugh JS, Awi D, Mendy M, Hill AV, Whittle H, McConkey SJ. Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection. PLoS One 2011; 6:e14626; PMID:21347224; http://dx.doi.org/10.1371/journal.pone.0014626.
63. Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, et al.; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 2011; 203:610-9; PMID:21282192; http://dx.doi.org/10.1093/infdis/ jiq105.
64. Greenough TC, Cunningham CK, Muresan P, McManus M, Persaud D, Fenton T, et al.; Pediatric AIDS Clinical Trials Group P1059 Team. Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. Vaccine 2008; 26:6883-93; PMID:18940219; http://dx.doi.org/10.1016/j.vaccine.2008.09.084.
65. Glaziou P, Floyd K, Raviglione M. Global burden and epidemiology of tuberculosis. [vii.]. Clin Chest Med 2009; 30:621-36, vii; PMID:19925958; http://dx.doi.org/10.1016/j.ccm.2009.08.017.
66. Rook GA, Lowrie DB, Hernàndez-Pando R. Immunotherapeutics for tuberculosis in experimental animals: is there a common pathway activated by effective protocols? J Infect Dis 2007; 196:191-8; PMID:17570105; http://dx.doi.org/10.1086/518937.
67. Lowrie DB, Tascon RE, Bonato VL, Lima VM, Faccioli LH, Stavropoulos E, et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999; 400:269-71; PMID:10421369; http://dx.doi.org/10.1038/22326.
68. Cardona PJ, Amat I, Gordillo S, Arcos V, Guirado E, Díaz J, et al. Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine 2005; 23:1393-8; PMID:15661388; http://dx.doi.org/10. 1016/j.vaccine.2004.09.008.
69. Mwinga A, Nunn A, Ngwira B, Chintu C, Warndorff D, Fine P, et al.; LUSKAR collaboration. Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial. Lancet 2002; 360:1050-5; PMID:12383985; http://dx.doi.org/10.1016/S0140-6736(02)11141-X.
70. Verreck FA, Vervenne RA, Kondova I, van Kralingen KW, Remarque EJ, Braskamp G, et al. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS One 2009; 4:e5264; PMID:19367339; http://dx.doi.org/10. 1371/journal.pone.0005264.
71. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004; 10:1240-4; PMID:15502839; http://dx.doi.org/10.1038/nm1128.
72. McShane H. Tuberculosis vaccines: beyond bacille Calmette-Guerin. Philos Trans R Soc Lond B Biol Sci 2011; 366:2782-9; PMID:21893541; http://dx.doi.org/10.1098/rstb.2011.0097.
73. Sander CR, Pathan AA, Beveridge NE, Poulton I, Minassian A, Alder N, et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am J Respir Crit Care Med 2009; 179:724-33; PMID:19151191; http://dx.doi.org/10.1164/rccm.200809-1486OC.
74. Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris M, Moyo S, et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis 2008; 198:544-52; PMID:18582195; http://dx.doi.org/10.1086/590185.
75. Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, Isaacs F, et al. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol 2010; 40:279-90; PMID:20017188; http://dx.doi.org/10.1002/eji. 200939754.
76. Ota MO, Odutola AA, Owiafe PK, Donkor S, Owolabi OA, Brittain NJ, et al. Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants. Sci Transl Med 2011; 3:88ra56; PMID:21697532; http://dx.doi.org/10.1126/ scitranslmed.3002461.
77. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al.; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-84; PMID:15930418; http://dx.doi.org/10.1056/NEJMoa051016.